Delving into the Latest Updates on Athenex Pharmaceuticals (China) Ltd. with Synapse

Overview

主要目的：向在研究 KX-ORAX-CN-007中完成了Oraxol治疗，获得完全缓解（CR），部分缓解（PR），或病情稳定（SD），且希望继续治疗的患者和其他转移性乳腺癌患者提供进一步治疗，并进一步评估Oraxol在乳腺癌患者中的安全性。次要目的：进一步评估Oraxol 在乳腺癌患者中的有效性

[Translation]

Primary objective: To provide further treatment to patients who have completed Oraxol treatment in study KX-ORAX-CN-007 and achieved complete remission (CR), partial remission (PR), or stable disease (SD) and wish to continue treatment, and to other patients with metastatic breast cancer, and to further evaluate the safety of Oraxol in patients with breast cancer. Secondary objective: To further evaluate the effectiveness of Oraxol in patients with breast cancer

Start Date29 Aug 2019

Sponsor / Collaborator

Athenex, Inc.

[+3]

CTR20191666

/ Active, not recruitingPhase 1

一项给予转移性乳腺癌患者Oraxol的延伸研究

[Translation] An extension study of Oraxol in patients with metastatic breast cancer

主要目的：向在研究 KX-ORAX-CN-007中完成了Oraxol治疗，获得完全缓解（CR），部分缓解（PR），或病情稳定（SD），且希望继续治疗的患者和其他转移性乳腺癌患者提供进一步治疗，并进一步评估Oraxol在乳腺癌患者中的安全性。次要目的：进一步评估Oraxol 在乳腺癌患者中的有效性

[Translation]

Primary objective: To provide further treatment to patients who have completed Oraxol treatment in study KX-ORAX-CN-007 and achieved complete remission (CR), partial remission (PR), or stable disease (SD) and wish to continue treatment, and to other patients with metastatic breast cancer, and to further evaluate the safety of Oraxol in patients with breast cancer. Secondary objective: To further evaluate the effectiveness of Oraxol in patients with breast cancer

Start Date29 Aug 2019

Sponsor / Collaborator

Athenex, Inc.

[+3]

CTR20190531

/ Active, not recruitingPhase 1

一项确定Oraxol在乳腺癌患者中药代动力学的临床研究

[Translation] A clinical study to determine the pharmacokinetics of Oraxol in breast cancer patients

主要目的：考察乳腺癌患者口服紫杉醇（Oraxol）的PK（AUC）次要目的：确定Oraxol在乳腺癌患者中的安全性和有效性（疗效率，无进展生存[PFS]），总生存[OS]）

[Translation]

Primary objective: To investigate the PK (AUC) of oral paclitaxel (Oraxol) in patients with breast cancer Secondary objective: To determine the safety and efficacy (efficacy rate, progression-free survival [PFS], overall survival [OS]) of Oraxol in patients with breast cancer

Start Date13 May 2019

Sponsor / Collaborator

Athenex, Inc.

[+3]

100 Clinical Results associated with Athenex Pharmaceuticals (China) Ltd.

Login to view more data

0 Patents (Medical) associated with Athenex Pharmaceuticals (China) Ltd.

Login to view more data

100 Deals associated with Athenex Pharmaceuticals (China) Ltd.

Login to view more data

100 Translational Medicine associated with Athenex Pharmaceuticals (China) Ltd.

Login to view more data